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T cell activation defect in hemodialysis patients: Evidence for a role of
the B7/CD28 pathway. The immunosuppressive effect of chronic renal
failure is correlated with an impaired proliferation of peripheral blood
leukocytes in Vitro. This is mainly due to an impaired function of the
accessory cells rather than the T cells. Here we tried to define a missing
accessory signal for T cell activation in hemodialysis patients. We
substituted cell surface bound molecules by adding tumor cell lines to
the in vitro assays that express different patterns of accessory mole-
cules. Cell lines that express the costimulatory B7 molecule reconsti-
tuted the activation of patients' cells whereas B7 negative cells did not.
The reconstitution was also achieved using mouse fibroblasts trans-
fected with human B7 or by monoclonal antibodies that stimulate the B7
ligand CD28 on T cells. These data further emphasize that impaired
leukocyte function in renal failure is due to an accessory cell defect, and
that T cells of these patients have normal functional capacities when
they get the costimulatory signals required. We demonstrate that it is
the B7/CD28 pathway that reconstitutes cellular functions in the pa-
tients. However, the short-term suppressive effects of uremic serum
cannot be compensated by additional costimulation via B7/CD28.
Chronic renal failure and maintenance hemodialysis treat-
ment lead to a state of immunodeficiency in most patients.
Clinically these patients suffer from frequent infectious compli-
cations and cannot be sufficiently protected against hepatitis B
or influenza by vaccination [1, 2]. In vitro investigations showed
a good correlation between reduced proliferation of peripheral
blood mononuclear cells (PBMC), impaired secretion of inter-
leukin-2 (IL-2) and enhanced expression of IL-2 receptor on
resting T cells with the clinical sequelae of immunodepression
[3, 4]. It has been shown that the response to hepatitis B
vaccine in these patients is a good predictor for the alteration of
the immune system by uremia and hemodialysis.
Earlier studies on the function of different cell populations
demonstrated that the in vitro abnormalities in PBMC of
hemodialysis patients were normalized by combination of the
patients' T cells with monocytes from healthy control persons.
On the other hand normal T cells showed less proliferation and
IL-2 secretion in the presence of monocytes from dialysis
patients than in the presence of monocytes from healthy per-
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Sons [4]. Until now the mechanism of this monocyte defect in
hemodialysis patients has not been completely understood.
Interaction of monocytes as antigen presenting cells and T
cells is based on three major pathways. The first signal is
derived by presentation of antigen on MHC class II molecules
of monocytes to the T cell receptor. In addition the interaction
of a number of receptor-ligand pairs on the surface of both cell
types is needed to induce T cell proliferation and effector
functions [5]. Besides this monocytes secrete soluble mediators
like IL-l, IL-6 and tumor necrosis factor alpha (TNFa) that
modulate T cell function. Only very few informations exist on
the role of surface bound signals in T cell activation of hemo-
dialysis patients. In the present study we tried to substitute a
possible defect of monocyte surface molecule signalling in
hemodialysis patients by in vitro addition of human tumor cells
that provide different patterns of accessory molecule expres-
sion.
One of the receptor-ligand systems providing costimulatory
signals is the B7 molecule on accessory cells binding to the
CD28 antigen on T cells [6]. The CD28 molecule has a signal
transduction pathway that mediates effects on T cells indepen-
dent of the T cell receptor. Stimulation of CD28 alone has no
measureable effects, but in conjunction with stimulation via the
T cell receptor complex it stabilizes mRNA for IL-2, resulting
in an enhanced and long-standing secretion of the protein [7].
Furthermore, a direct effect of the CD28 signal on IL-2 gene
transcription has also been shown [8]. Given these features, a
defect in B7/CD28 interaction possibly could lead to a reduced
IL-2 secretion and proliferation of T cells similar to the situation
observed in hemodialysis patients.
In the present study we demonstrated an important role for
the B7/CD28 ligand-receptor system to normalize in vitro pa-
rameter of PBMC function of hemodialysis patients.
Methods
Patients
We studied 24 patients on chronic hemodialysis treatment.
Their mean age was 58.5 11 years (responder 57.5 11.5,
nonresponder 59.6 10.1). End-stage renal disease had oc-
curred due to the following diseases: chronic glomerulonephri-
tis (7), diabetic nephropathy (7), nephrosclerosis (4), analgesic
nephropathy (1), amyloidosis (1), and unknown etiology (4).
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Regular hemodialysis was performed using dialyzers with Cu-
prophane membranes and bicarbonate dialysate. The mean
length of treatment was 4.5 hours three times a week. Dialyzers
were not reused. The control group consisted of 12 healthy
individuals from our laboratory personnel, mean age was 33
8.4 years. Patients were classified as responders or nonre-
sponders according to their antibody production following four
injections of 40 jig hepatitis B vaccine (Engerix B, Smith Kline
Dauelsberg, GOttingen, Germany) at 0, 1, 6 and 9 months.
Nonresponders had <10 lU/mi antiHBs at two determinations
between months 9 and 12, responders had 10 lU/mi. In order
to avoid bias on proliferation data the experiments were always
performed using blood specimen of a control person, a re-
sponder and a nonresponder at one time.
Preparation of cells
Twenty ml of heparinized venous blood were drawn from
patients immediately before hemodialysis. Mononuclear cells
were preparated by density gradient centrifugation on Ficoll
density 1.077 (Biochrom, Berlin, Germany). T cells were puri-
fied by rosetting with sheep erythrocytes (BAG, Lich, Ger-
many) followed by antibody dependent lysis of monocytes.
Therefore the cell pellet was incubated with 600 jii anti-
monocyte antibody BMA 0210 (Behring, Marburg, Germany) at
a concentration of 0.25 jig/mi for 45 minutes at 4°C followed by
a 60 minute incubation at 37°C with 900 pl rabbit complement
(Behring, Marburg, Germany) diluted 1:3. Cells were washed
twice in PBS and incubated overnight in RPMI 1640 medium +
5% fetal calf serum (FCS) in plastic petri dishes (Nunc, Wies-
baden, Germany).
Cell lines
Cells of the human Burkitt's lymphomas Raji and Daudi and
the human histiocytoma U937 (American Type Culture Collec-
tion ATCC) were cultured in RPMI 1640 + 5% FCS. Murine
fibrobiast cells 3T6 were cultured in ISCOVE's medium + 10%
FCS. All media were supplemented with 2 mri giutamine and 50
jig/mi gentamicin. As the 3T6 is a murine cell line, it does not
express any human surface antigens that interfere with T cell
function. 3T6-B7/FcyII is a cell derived from this line by
transfection with the human B7 and the FcyII receptor. These
cells were provided by Dr. M. de Boer (Innogenetics, Ghent,
Belgium) [9]. 3T6-B7/FcyII were cultured with 200 mM geneti-
cm (G418, Sigma, Deisenhofen, Germany). To avoid further
proliferation of the tumor cell lines in the assay all these cells
were treated with 500 jig/ml mitomycin C (Sigma) for 60
minutes and washed twice with PBS before use in proliferation
assays. After this treatment the cell lines had a 3H-thymidine
uptake resulting in less than 200 cpm.
Proliferation assays
PBMC or purified T cells were used at 2.5 X io per well.
Cells were incubated in 96-well round bottom microtiter plates
(Costar #3799, Cambridge, Massachusetts, USA) in serum free
medium (CG Medium, Camon, Wiesbaden, Germany) supple-
mented with 2 mrvi glutamine and 50 jig/ml gentamicin. Cells
were stimulated by phytohemagglutinin (PHA-P, Wellcome) 0.2
jig/mi. Additional cell lines were added at 5 x l03/well. For the
evaluation of antiCD28 antibodies, PBMC or T cells were
preincubated with 100 1d of a 1:10 dilution of Leu-28 (Becton
Dickinson, Mountain View, California, USA) for 90 minutes
before use in the test. After 72 hours of incubation the tests
were pulsed with 0.5 jsCi/well 3H-thymidine for another 16
hours, and then harvested and counted in a liquid scintillation
counter (Betaplate 1205, Pharmacia, Sweden). All tests were
performed in triplicate. The effects of uremic serum were
evaluated using PBMC of healthy donors with blood-group 0.
Sera were heat-inactivated (56°C, 30 mm) and added at a final
concentration of 3% to the medium. AntiCD28 antibodies were
titrated to their the maximum effect and thus added to the test
at a final concentration of 1 jig/mi.
Determination of secreted IL-2
IL-2 was determined by bioassay using IL-2 dependent
CTLL-2 cells [10]. Supernatants were harvested after 24 hours
and frozen. As standard recombinant IL-2 (Proleukin, Cetus)
was used. The test had a detection limit of 200 pg/mI. All tests
were performed in triplicate with a standard deviation of the
values less than 10%. Samples were measured using undiluted
and 1:6 diluted supernatants.
Flow cytometric analysis of cell lines
The following antibodies were used: lOT 2a-FITC (HLA-
class II; Dianova, Hamburg, Germany), 10L54-FITC (CDS4/
ICAM-l; Dianova), TS1/22 (CD11aJLFA-1) [11], TS2/9 (CD58/
LFA-3) [11], BB1(B7) [121. Goat anti-mouse F(ab)2-FITC
(Medac, Hamburg, Germany) was used as secondary antibody.
Flow cytometry was performed using a FACScan flow cytom-
eter (Becton Dickinson).
Statistical analysis
Data were described as mean standard deviation. Calcula-
tion of P values for difference between groups was done by
Students t-test.
Results
Proliferation and IL-2 production of PBMC following
stimulation by PHA
We compared mean proliferation values of 24 hemodialysis
patients and 12 healthy controls. Proliferation of unfractionated
PBMC from hemodialysis patients was lower compared to
healthy controls (patients vs. controls, P < 0.01). Among the
patients the cells obtained from nonresponders to hepatitis B
vaccine showed an even lower proliferation than cells from
responders (responder vs. nonresponder, P < 0.05). There was
no significant difference between controls and responders (P>
0.1, Fig. la). IL-2 secretion by PBMC was very low in all tests.
This resulted from the low cell number per well which was used
to make cell-cell interaction a more limiting factor compared to
tests with higher cell numbers. Yet the secretion was still
detectable in all tests. It was higher in the control group than in
either of the patients' groups (responder vs. controls P < 0.01,
nonresponder vs. controls P < 0.05; Fig. ib).
Proliferation of purjfied T-cells in presence of Raji cells
The in vitro use of cells of the human Burkitt's lymphoma
Raji as accessory cells instead of the autologous monocytes
only slightly increased T cell proliferation in the control group
(P> 0.2). In contrast, PHA driven proliferation of T cells from
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difference between the proliferation of cells from patients and
controls or responders and nonresponders (P > 0.3 for all
comparisons). This makes a suppressive effect of autologous
monocytes from patients unlikely (Fig. 2). In contrast to the
effect of Raji cells the addition of cells of the Burkitt's lym-
phoma Daudi or the histiocytoma U937 did not normalize
proliferation in patients' cells at all (Daudi: patients vs. controls
P < 0.05; U937: patients vs. controls; P < 0.05). These cell
lines had a slight costimulatory effect in the control group (Fig.
2).
Phenotypic characterization of the tumor cell lines
As shown in Figure 3 there are a nuthber of differences in
surface expression of accessory molecUles in the cell lines used.
Expression of HLA class II molecules was high in Raji and
Daudi and absent in U937. These molecules should not have
much influence on the PHA driven T cell stimulation. Expres-
sion of LFA-l and LFA-3 was high in all cells so that contri-
bution of these molecules to the observed effects is not likely.
As ICAM-l was expressed on Daudi cells it should not be
responsible for the effect as well. The main difference that
discriminates Raji cells from the other two lines is the high
expression of B7 antigen that can only be found at a very low
level on Daudi cells and is absent on the U937 line.
B7 transfected murine fibroblasts 3T6 also normalize PBMC
function in vitro
To study whether the high expression of B7 on Raji cells is
responsible for the normalization of functional parameters of
patients' cells we used murine fibroblasts expressing a trans-
fected human B7 molecule. Eighty percent of the cells of the
murine fibroblast line 3T6 transfected with both the human
FcyII receptor and human B7 genes expressed the B7 molecule
on their surface (data not shown). Untransfected 3T6 cells had
no influence on proliferation and IL-2 secretion of PBMC either
from patients or controls. B7 transfected cells had a slight
costimulatory effect on proliferation of PBMC from controls
and enhanced proliferation of patients' cells nearly to the
normal level. Secretion of IL-2 was not changed by the cocul-
ture with native 3T6 cells but was substantially enhanced by
P<0.01
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Fig. 2. Proliferation of PBMC from hemodialysis patients and controls
in the presence of mitomycin treated cells of the Burkitt's lymphomas
Raji and Daudi and the histiocytoma U937. Symbols are: (D) controls;() responders; () nonresponders.
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Fig. 1. Prohferation (A) and IL-2 secretion (B) by PBMC and purified
T cells plus Raji cells from chronic hemodialysis patients and healthy
controls (D) upon stimulation by PHA. Patients were classified as
responder () or nonresponder () according to their antibody pro-
duction following hepatitis B vaccination (Methods). Bars represent
mean values standard deviation of 12 patients in each group. (Part A:
P < 0.05 responder vs. nonresponder; P < 0.01 controls vs. nonre-
sponders; Part B: P < 0.05 controls vs. responder and controls vs.
nonresponder).
patients was strongly enhanced so that they reached the same
level as controls. A difference between responders and nonre-
sponders was no longer observed (P >0.5 for all comparisons).
The allogeneic stimulation of T cells by Raji cells was less than
10% of the PHA driven proliferation in all tests (Fig. la). The
substitution of monocytes by Raji cells strongly enhanced IL-2
secretion in all groups. In this setting patients' cells reached
normal levels of IL-2 secretion (patients vs. controls P > 0.9;
Fig. lb).
Costimulatory effect of different tumor cell lines on PBMC
In order to rule out a suppressive effect of the autologous
monocytes in hemodialysis patients we added Raji cells to
Unfractionated PBMC. The Raji cells enhanced proliferation in
all three groups and patients' cells reached the same level of
proliferation as healthy controls. There was statistically no
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3T6-B7. Their addition lead to a normal IL-2 secretion also in
cells of hemodialysis patients. A difference between responders
and nonresponders was not observed (Fig. 4).
Intact CD28 costimulatory pathway in dialysis patients
To further confirm the role of the B7/CD28 interaction in
these effects we used monoclonal antibodies to the CD28
antigen on I cells. Preincubation of purified T cells with
antiCD28 prior to their stimulation by PHA lead to equally high
levels of proliferation and IL-2 secretion in all three groups (P
> 0.5 for all comparisons). So in this system which is indepen-
dent of any accessory cell normal parameters of T cell function
were obtained even for nonresponders. We also performed
these tests using unfractionated PBMC. Again proliferation was
greatly enhanced in patients' cells and the difference to controls
disappeared. The values for nonresponders tended to be some-
what lower. Although this was statistically not significant (P =
0.1) a suppressive effect of monocytes from nonresponders can
not fully be ruled out. IL-2 secretion of PBMC after stimulation
with antiCD28 and PHA was enhanced in all groups and
completely normalized in patients (Fig. 5).
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Fig. 4. Effect of murine 3T6fibroblasts and 3T6 cells transfected with
human Fcy!J receptor and human B7 on PHA driven proliferation of
PBMC from hemodialysis patients and healthy controls (N = 6foreach
group). Symbols are: (U) PBMC + PHA; (D) PBMC + PHA -I- 3T6;(Li) PBMC + PHA + 3T6-B7,
Uremic serum has suppressive effects on normal PBMC in
vitro that are not neutralized by antiCD28
Proliferation of normal PBMC was inhibited by 3% heat
inactivated serum from chronic hemodialysis patients but not
by serum from healthy controls (patients vs. controls P < 0.05).
The addition of antiCD28 had a costimulatory effect both in the
presence of normal or patients' serum. But proliferation in the
presence of serum from nonresponders remained lower. The
acute suppressive effect of patients' serum after short term
incubation for 48 h was not normalized by antiCD2S at concen-
trations of the antibody titrated to have the maximum effect
(patients vs. controls P < 0.05; Table 1).
Discussion
The immune defect in patients with chronic renal failure and
regular hemodialysis is characterized by frequent infectious
complications [13] and reduced efficacy of clinical vaccinations
[1, 2]. Many studies correlated these clinical findings with a
reduced proliferation of peripheral blood mononuclear cells
(PBMC) in vitro to various stimuli [14—16]. A correlation
between the effect of hepatitis B vaccination and the in vitro
proliferation of PBMC suggests a causal relation between in
vitro data and clinical outcome [41. In the present study we
found a reduced proliferation upon stimulation by PHA of
PBMC from those patients on hemodialysis that had no suffi-
cient response to hepatitis B vaccination. Cells from patients
who had developed a protective antibody titer against hepatitis
B showed an intermediate level of proliferation between non-
responders and controls. The average age of our control group
was lower than in the patient groups. While T cell function
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FIg. 3. Flow cytometric determination of the surface expression pat-
tern of MHC class ii molecules and accessory molecules on Raji,
Daudi and U937 cells.
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Fig. 5. Proliferation (A) and JL-2 secretion (B) of PBMC or purified T
cells from patients and controls upon stimulation by PHA and costim-
ulation by antiCD28 monoclonal antibodies. (Part A: P < 0.05 re-
sponder vs. nonresponder; P < 0.01 controls vs. nonresponders; Part
B: P < 0.05 controls vs. responder and controls vs. nonresponder).
Symbols are: (Eu) controls; () responder; () nonresponder.
Table 1. Proliferation of PBMC from a normal donor (blood group
0) upon stimulation by PHA in the presence of 3% heat-inactivated
serum either from hemodialysis patients or healthy controls
Serum source
PHA
PHA +
antiCD28
cpm
Controls 70.812a 18.865 98.196a 16.758
Responder 60.195 17.509 86.410 20.168
Nonresponder 52.473a 16.596 78.323a 16.456
Mean standard deviations of experiments with 11 serum donors in
each group.
a Controls vs. nonresponder P < 0.05
diminishes in the elderly the function of the antigen presenting
cells remains stable [17]. As there was no difference in age
between responders and nonresponders this factor seems to be
unlikely to explain the reduced proliferation.
Reduced proliferative capacities of PBMC in chronic renal
failure are attributed to a low secretion of the auto- and
paracrine T cell growth factor interleukin-2 (IL-2). IL-2 secre-
tion is low due to an impaired inducibility of the IL-2 gene in
PBMC [181. Exogenous supplementation with IL-2 can normal-
ize in vitro proliferation of PBMC and in vivo reactivity to
hepatitis B vaccination [19, 20]. Confirming a number of previ-
ous studies [14, 21] we could show a reduced secretion of IL-2
into the supernatant by the patients' cells. In the present study
the cell numbers per well were titrated to the minimum that
allowed stable proliferation upon PHA to make cell-cell inter-
actions a limiting factor in the assay. Resulting levels of IL-2 in
the supernatant were therefore very low but could be detected
in all samples.
Proliferation assays and IL-2 determinations primarily mea-
sure the functionality of T cells. However, there are good
reasons to believe that the accessory cells, in peripheral blood
mainly the monocytes, are the cell population that undergoes
alterations by chronic uremia and hemodialysis. Earlier studies
found that the impaired proliferation of PBMC from hemodial-
ysis patients upon antiCD3 stimulation can be normalized by
substituting the patients' monocytes by adherent cells of normal
control persons. Moreover, normal T cells showed a reduction
of their proliferative capacities upon incubation with uremic
monocytes [4]. It was also demonstrated that monocytes from
hemodialysis patients had an impaired capacity to present
nominal antigen to MHC compatible normal T cells [22].
Activation of CD4+ T cells by antigen requires at least two
signals of the antigen presenting cell (APC). The first signal is
derived from the processed antigen presented in the context of
the MHC class II molecule. Essential or modulating second
signals arise from the binding of numerous accessory molecules
on the APC with their ligands on the T cell [5]. Major adhesion
and costimulatory systems are the interaction of LFA- 1 with
ICAM-1, LFA-3 with CD2 and B7 with CD28. As blocking of
each of these pathways by monoclonal antibodies inhibits T cell
activation to some degree [5] a functional defect in one of these
systems would possibly induce an impaired T cell activation.
Cytokines like IL-l, IL-6 and TNFa have further modulating
influences on the activation of T cells. Until now little has been
known about the function of the cell surface bound costimula-
tory molecules in renal failure patients.
In analogy with the experiments quoted above in which
patients' monocytes were exchanged with healthy monocytes
[4] we used human tumor cell lines with different patterns of
accessory molecule expression as costimulus in vitro. These
cells are able to reconstitute the in vitro response of normal
purified T cells that alone only weakly respond to stimulation by
PHA. Cells of the Burkitt's lymphoma Raji as accessory cells
reconstitute proliferation and IL-2 secretion of purified T cells
from patients as well as they did with normal T cells. Both
parameters reached normal levels in patients regardless of their
in vivo response to hepatitis B vaccination. This result further
demonstrates the normal functional capacities of T cells from
hemodialysis patients in the presence of competent accessory
cells.
It had to be ruled out that this normalization was the result of
the removal of suppressive cells. Modai et al [23] described the
induction of suppressive adherent cells by incubation in uremic
serum. They confirmed studies in animal models of chronic
P6MG T cells T cells PBMC
P<O.05
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uremia from the early 80's that found suppressive adherent cells
as well [24]. In the present study Raji cells also normalized
proliferation of unfractionated PBMC in dialysis patients. This
argues strongly against a suppressive effect of autologous
monocytes. It seems more likely that the Raji cells supplement
costimulatory signals that are lacking in the autologous acces-
sory cell.
The addition of cells of the Burkitt's lymphoma Daudi or the
histiocytoma U937 had a slight costimulatory effect on normal
PBMC as well. But in contrast to the Raji cells proliferation of
patients' cells was not reconstituted to the level of normal
controls. The difference between patients and controls re-
mained the same as in the assays without costimulatory tumor
lines. The enhancement of proliferation in normal cells can be
explained by the higher density of accessory molecules on the
cell lines compared to resting normal monocytes. Comparison
of the expression of a number of accessory molecules on these
cell lines revealed that the expression pattern of the B7 mole-
cule correlated best with the effect on the patients' cells.
The B7 molecule was first described on activated B cells but
can also be found on monocytes [25]. Ligation of class II
molecules and/or intracellular second messenger cAMP are
important factors regulating its expression [26]. 87 binds to the
CD28 receptor present on 90% of CD4+ and 50% of CD8+ T
cells [6]. It was also shown to bind the CTLA-4 molecule that is
expressed on T cells [27, 28]. While the B7/CTLA-4 interaction
seems to have a more mechanical adhesion function the inter-
action of B7 with CD28 derives an important costimulatory
signal for T cell activation [28].
In mixed lymphocyte cultures a blockade of the B7/CD28
pathway by antibody or a soluble CTLA-4 immunoglobulin
fusion protein strongly inhibits T cell activation [27]. This
emphasizes the importance of the signal for T cell activation.
Stimulation of purified T cells or Jurkat cells (a human T cell
lymphoma used as a model of resting T cells) with antiCD3
induces no significant IL-2 secretion until an additional signal
via CD28 is given [8]. Moreover, in some models antigen
specific stimulation via the T cell receptor without a second
signal was shown to induce a long lasting state of unresponsive-
ness to further stimulation in these cells [29]. The B7/CD28
pathway is thought to be one of the signals that can prevent
functional anergy [30]. Given this important role for T cell
activation a functional defect of the B7/CD28 pathway could
result in an impaired cellular reaction to antigens in vivo and a
reduced in vitro proliferation and IL-2 secretion of PBMC
similar to that seen in hemodialysis patients.
Our data clearly show that the critical molecule mediating the
reconstitution of T cell functions in patients' cells is B7. This
can be seen from the specific effect of 87 transfectants and from
the effect of antiCD28 antibodies. In nonresponders the level of
proliferation reached by PHA plus antiCD28 seemed to be
slightly lower than in responders although this could not be
proven statistically. In comparison with the experiments in
purified T cells where a complete normalization of proliferation
was achieved an additional effect of PBMC that cannot be
completely neutralized by B7/CD28 costimulation cannot be
ruled out.
Providing costimulation by the B7 molecule is able to nor-
malize in vitro functional parameters of T cells from chronic
hemodialysis patients. As a reduced IL-2 transcription upon
stimulation of PBMC has been shown to be involved in the
uremic immune suppression [18] a defect of the B7/CD28
system that induces IL-2 transcription might play a role in the
pathogenesis. Further studies will have to focus on the question
whether this effect arises from a lack of B7 activity in these
patients. Impaired B7 expression on antigen presenting cells or
soluble inhibitors of the B7/CD28 interaction could contribute
to this effect. Another possibility that until now cannot be ruled
out from our data is that the additional costimulation via
B7/CD28 provided by Raji cells or 87 transfectants overrides a
different defect of T cell activation. This would be an effect
similar to that of CD28 on the inhibition of IL-2 transcription by
cyclosporin A. In peripheral blood T cells the cyclosporin A
insensitive CD28 costimulation overcomes the block on IL-2
transcription [8]. Using flow cytometry we could not yet show
a reduced expression of 87 in the patients because 87 expres-
sion on monocytes is generally rather low. This makes it
difficult to evaluate differences between individuals, especially
when examining Fc-receptor positive cells.
However, a reduced 87 function in these patients could
certainly not explain the whole range of immunosuppressive
features of uremia. Serum from patients on hemodialysis sup-
presses the proliferation of normal PBMC [19]. This suppres-
sion was even stronger by sera from patients that had a more
pronounced clinical defect, the nonresponders. This suggests a
pathophysiological role for serum factors. By incubation of
normal cells in uremic serum compared with patients' cells
incubated both in normal and patients' serum Dumann, Meuer
and Kohler [19] could demonstrate the coexistence of long-term
cellular alterations in hemodialysis patients and short-term in
vitro effects of uremic serum on normal cells. In our assay we
could compensate the chronic cellular alterations in these
patients by supplementation of the 87 expression. We failed to
compensate the short-term effects of uremic serum by antiCD28
antibodies. It is thus likely that uremic serum has immunosup-
pressive effects that are not only directed at the accessory cells
but on the T cells as well. Therefore they cannot be influenced
by the substitution of a signal from accessory cells.
In summary, we have shown the reversal of the impaired in
vitro function of peripheral blood mononuclear cells in chronic
hemodialysis patients by supplementation of the costimulatory
pathway B7/CD28. This suggests a role of the B7/CD28 path-
way for the uremic immune defect as this pathway is mainly
directed at the IL-2 transcription which has been shown to be
impaired in these patients.
Acknowledgments
This work was supported by grant # 01 K! 8914/S of the Bundesmin-
isterium für Forschung und Technologie. The authors wish to thank Dr.
C. Renschin whose patients were included in the study and Dr. M.
Hegen for many helpful discussions.
Reprint requests to Prof Dr. H. KOhler, First Department of
Medicine, Johannes Gutenberg Universitat Mainz, Langenbeckstrasse
1, DW-6500 Mainz, Germany. a
References
I. KOHLER H, ARNOLD W, RENSCHIN C, DORMEYER HH, MEYER
ZUM BO5CHENFELDE KH: Active hepatitis B vaccination of dialy-
sis patients and medical staff. Kidney mt 25:124—128, 1984
Girndt et al: B7/CD28 pathway in dialysis patients 365
2. CAPPEL R, VAN BEERS D, LIESNARD C, DRATWA M: Impaired
humoral and cell-mediated immune responses in dialyzed patients
after influenza vaccination. Nephron 33:21—25, 1983
3. DUMANN H, MEUER SC, MEYER ZUM BUSCHENFELDE KH,
KOHLER H: Hepatitis B vaccination und interleukin 2 receptor
expression in chronic renal failure. Kidney ml 38:1164—1168, 1990
4. MEUER SC, HAUER M, Kuiz P, MEYER ZUM BUSCHENFELDE KH,
KOHLER H: Selective blockade of the antigen-receptor-mediated
pathway of T cell activation in patients with impaired immune
responses. J Gun Invest 80:743—749, 1987
5. Lw Y, LINSLEY PS: Costimulation of T-cell growth. Curr Op
Immunol 4:265—270, 1992
6. DAMLE NK, MOHAGHEGHPOUR N, HANSEN JA, ENGLEMAN EG:
Alloantigen-specific cytotoxic and suppressor T lymphocytes are
derived from phenotypically distinct precursors. J Immunol 131:
2296—2300, 1983
7. LINDSTEN T, JUNE CH, LEDBETTER JA, STELLA G, THOMPSON
CB: Regulation of lymphokine messenger RNA stability by a
surface-mediated T cell activation pathway. Science 244:339—343,
1989
8. WILLIAMS TM, MOOLTEN DM, MAKNI H, KIM HW, KANT JA,
KAMOUN M: CD28-stimulated IL-2 gene expression in Jurkat T
cells occurs in part transcriptionally and is cyclosporine-A sensi-
tive. J Immunol 148:2609—2616, 1992
9. DE BOER M, PARREN P, DOVE J, OSSENDORP F, VAN DER HORST
G, REEDER J: Functional characterization of a novel anti-B7
monoclonal antibody. Eur J Immunol 22:3071—3075, 1992
10. GILLIs 5, FERN MM, Ou W, SMITH KA: T cell growth factor:
Parameters of production and a quantitative microassay for activ-
ity. J Immunol 120:2027, 1978
11. MCMICHAEL AJ: Leucocyte Typing III. Oxford, Oxford University
Press, 1987, p. 1048
12. YOKOCHI T, HOLLY RD, CLARK EA: B lymphoblast antigen (BB.l)
expression on Epstein-Barr virus activated B cell blasts. J Immunol
128:823, 1982
13. US RENAL DATA SYSTEM: 1990 annual report. Am J Kidney Dis
l6(Suppl 2):44—52, 1990
14. DONATI D, DEGIANNIS D, HOMER L, GASTALDI L, RASKOVA J,
RASKA K: Immune deficiency in uremia: Interleukin-2 production
and responsiveness and interleukin-2 receptor expression and re-
lease. Nephron 58:268—275, 1991
15. Kua.z P, KOl-ILER H, MEUER SC, HUTTEROTH T, MEYER ZUM
BUSCHENFELDE KH: Impaired cellular immune responses in
chronic renal failure: Evidence for a T cell defect. Kidney mt
26:1209—1214, 1986
16. GHI0 R, HAUPT E, PIsT0IA V, PERATA A, MINALE P, RATTI M,
BoccAcclo P: Impaired in vitro growth of PHA induced T lympho-
cyte colonies in hemodialyzed renal failure patients. B/ut 50:135—
140, 1985
17. MILLER RA: Aging and immune function. mt Rev Cytol 124:187—
215, 1991
18. GEREZ L, MADAR L, SHKOLNIK T, KRISTAL B, ARAD G, RESHEF
A, STEINBERGER A, KETZINEL M, SAYAR D, SHASHA S,
KAEMPFER R: Regulation of interleukin-2 and interferon-7 gene
expression in renal failure. Kidney mt 40:266, 1991
19. DUMANN H, MEUER SC, KOHLER H: Uremic serum inhibits
monocyte-dependent, but not interleukin-2-dependent steps of T
cell proliferation. Nephron 56:162—165, 1990
20. MEUER SC, DUMANN H, MEYER ZUM BOSCHENFELDE KH,
KOHLER H: Low dose interleukin-2 induces systemic immune
responses against HBsAg in immunodeficient non-responders to
hepatitis B vaccination. Lancet 1:15—18, 1989
21. BEAURAIN G, NARET C, MARCON L, GRATEAU G, DRUEKE T,
UREFA P, NELSON DL, BACH JF, CHATENOUD L: In vivo T cell
preactivation in chronic uremic hemodialyzed and non-hemodia-
lyzed patients. Kidney mt 36:636—644, 1989
22. GIBBONS RA, MARTINEZ OM, GAROVOY MR: Altered monocyte
function in uremia. C/in Immunol Immunopathol 56:66—80, 1990
23. MODAl D, BERMAN 5, COHEN D, AMIT M, COHN M, WEISSGARTEN
J, AVERBUKH Z: Induction of suppressor cell activity by cyclospo-
rin A and/or uremic serum in normal versus uremic peripheral
blood mononuclear cells. mt Arch Allergy App! immunol 91:291—
296, 1990
24. ALEVY YG, SLAVIN RG: Immune response in experimentally
induced uremia. II. Suppression of PHA response in uremia is
mediated by an adherent, Ia-negative and indometacin-insensitive
suppressor cell. J Immunol 126:2007—2010, 1981
25. FREEMAN GJ, FREEDMAN AS, SEGIL JM, LEE G, WHITMAN F,
NADLER LM: B7, a new member of the Ig superfamily with unique
expression on activated and neoplastic B cells. J Immunol 143:
2714—2722, 1989
26. NABAVI N, FREEMAN GJ, GAULT A, GODFREY D, NADLER LM,
GLIMCHER LH: Signalling through the MHC class II cytoplasmic
domain is required for antigen presentation and induces B7 expres-
sion. Nature 360:266—268, 1992
27. LINSLEY PS, BRADY W, URNES M, GROSMAIRE LS, DAMLE NK,
LEDBETTER JA: CTLA-4 is a second receptor for the B cell
activation antigen B7. J Exp Med 174:561—569, 1991
28. LINSLEY PS, GREENE JL, TAN P, BRADSHAW J, LEDBETTER JA,
ANASETTI C, DAMLE NK: Coexpression and functional coopera-
tion of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med
176: 1595—1604, 1992
29. SCHWARTZ RH: A cell culture model for T lymphocyte clonal
anergy. Science 248:1349—1356, 1990
30. HARDING FA, MCARTHUR JG, GROSS JA, RAULET DH, ALLISON
JP: CD28-mediated signalling co-stimulates murine T cells and
prevents induction of anergy in T cell clones. Nature 356:607—609,
1992
